Hormonal
GLP-1 receptor agonists induce significant fat mass loss with a non-significant or significantly smaller reduction in muscle mass, resulting in muscle mass accounting for less than 20% of total weight loss.
If you are taking a GLP-1 medication like Ozempic or Wegovy, your body is prioritizing fat loss over muscle loss. While you may lose a small amount of muscle, it is a minor fraction of your total weight loss (under 20%). Focus on maintaining strength through resistance training to preserve the muscle you have, but do not let fear of muscle loss stop you from using effective weight management tools.
In both populations, the reduction in measures of MM accounted for less than 20% of the total weight reduction.
Why this rating
Systematic review and meta-analysis of 38 publications (1735 participants) with separate analyses for T2DM and non-T2DM groups.
Source
How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
Oluwaseun Anyiam et al. · Obesity Reviews · 2025
DOI 10.1111/obr.13916
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →